December 8, 2025BloodOpen Access

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

View Full Paper

Ask AI

Bookmark

Authors

JRJoslyn RudoniCleveland Clinic JMJessica McElweeLevine Cancer Institute SAShebli AtrashLevine Cancer Institute

Discussion

Member takes

Implication

Observational analysis found supportive care effectively managed low-grade cytokine release syndrome in multiple myeloma, suggesting reduced reliance on immunosuppressive therapy.

Key Points

Supportive care alone managed low-grade cytokine release syndrome with similar outcomes to dexamethasone or tocilizumab.
Among 555 patients, 28% were managed effectively using supportive care only for their CRS.
Patients managed with supportive care had more grade 1 CRS events yet experienced comparable hospitalization durations.
Findings imply that supportive care can reduce the need for pharmacologic interventions in low-grade CRS.

Cite This Study

Rudoni et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9cc https://doi.org/10.1182/blood-2025-4579

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis found supportive care effectively managed low-grade cytokine release syndrome in multiple myeloma, suggesting reduced reliance on immunosuppressive therapy.

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Discussion

Member takes

Implication

Key Points

Cite This Study

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider